Cardiac Ablation Devices: Which Hospitals Are Expanding Their Electrophysiology Capacity?

Hospitals are expanding electrophysiology (EP) capacity to treat more patients with atrial fibrillation (AFib) and other abnormal heart rhythms. For cardiac device manufacturers, these investments create opportunities in ablation catheters, mapping systems, generators, imaging, and procedure-support technologies.

In October 2026, Tallahassee Memorial HealthCare announced a $20 million investment in a 14,500-square-foot Heart Rhythm Lab expansion. The project adds two EP procedure suites, a 12-bed pre- and post-procedure unit, and Abbott's Volt pulsed field ablation (PFA) system. This is a direct example of hospital investment creating demand for cardiac technology.

Download Customized and Ready to Use Well Researched PDF Samples: https://www.towardshealthcare.com/download-sample/5120 

Which Hospitals Are Expanding Capacity?

These examples show different stages of investment: building new facilities, increasing procedure capacity, and adopting newer ablation technologies. They do not represent a complete ranking of hospitals by purchasing activity.

PFA Is Creating a New Equipment Opportunity

Pulsed field ablation uses electrical pulses to target cardiac tissue responsible for abnormal rhythms. Unlike traditional radiofrequency ablation, which uses heat, PFA uses a different energy mechanism designed to selectively affect cardiac tissue.

In November 2024, the US FDA approved Johnson & Johnson MedTech's VARIPULSE platform for paroxysmal AFib. Medtronic's Affera system also received FDA approval in October 2024 for treating AFib and typical atrial flutter. These approvals demonstrate growing competition among established device manufacturers.

For hospitals, the decision involves more than purchasing a generator. They must assess catheter costs, mapping compatibility, staff training, procedure-room availability, maintenance, and clinical evidence.

Market Gaps and Business Opportunities

The strongest entry opportunities may sit around the core ablation platform rather than in building a complete system from scratch.

• Cost-effective consumables: Develop validated accessories and workflow products that address recurring procedural costs.

• EP lab efficiency: Build software for scheduling, equipment utilisation, inventory, and procedure-cost analysis.

• Mapping and imaging support: Develop complementary technologies that help clinical teams integrate equipment and manage procedural workflows.

• Training and simulation: Provide tools that help hospitals train staff and support the adoption of new ablation techniques.

For emerging manufacturers, an entry-level strategy is to validate one specific hospital problem, work with clinical and technology partners, and demonstrate measurable value before expanding. Any device must meet the applicable regulatory and safety requirements.

What Investors Should Watch

The key opportunity is the gap between increasing EP capacity and the cost of operating it. Hospitals investing millions in facilities need equipment that supports safe procedures, reliable utilisation, and sustainable costs.

Manufacturers that can prove clinical value, fit existing workflows, and offer dependable service may be better positioned to win hospital contracts than those competing on technical features alone.

About Us

Healthcare WebWire is powered by Towards Healthcare is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium